Theseus Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-22.92 Insider Own0.90% Shs Outstand38.25M Perf Week-5.67%
Market Cap292.06M Forward P/E- EPS next Y-1.63 Insider Trans111.91% Shs Float37.32M Perf Month-31.74%
Income- PEG- EPS next Q-0.30 Inst Own90.10% Short Float3.04% Perf Quarter-36.13%
Sales- P/S- EPS this Y-120.70% Inst Trans0.10% Short Ratio24.57 Perf Half Y-62.39%
Book/sh6.22 P/B1.15 EPS next Y33.30% ROA- Target Price21.50 Perf Year-
Cash/sh5.69 P/C1.26 EPS next 5Y- ROE- 52W Range6.95 - 24.54 Perf YTD-43.53%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-70.82% Beta-
Dividend %- Quick Ratio43.60 Sales past 5Y- Gross Margin- 52W Low3.02% ATR1.04
Employees26 Current Ratio43.60 Sales Q/Q- Oper. Margin- RSI (14)36.18 Volatility8.91% 13.68%
OptionableNo Debt/Eq0.00 EPS Q/Q-256.40% Profit Margin- Rel Volume1.98 Prev Close6.99
ShortableYes LT Debt/Eq0.00 EarningsMar 10 BMO Payout- Avg Volume46.19K Price7.16
Recom1.20 SMA20-12.36% SMA50-32.86% SMA200-41.52% Volume91,541 Change2.43%
Nov-01-21Initiated Wedbush Outperform $24
Nov-01-21Initiated SVB Leerink Outperform $28
Nov-01-21Initiated Jefferies Buy $23
Nov-01-21Initiated Cantor Fitzgerald Overweight $25
May-19-22 08:30AM  
May-18-22 08:30AM  
May-12-22 07:00AM  
Apr-20-22 10:16AM  
Apr-08-22 01:00PM  
Apr-05-22 08:30AM  
Mar-10-22 07:00AM  
Mar-08-22 05:01PM  
Feb-09-22 07:30AM  
Feb-02-22 07:30AM  
Jan-07-22 09:07AM  
Dec-17-21 08:00AM  
Nov-15-21 07:00AM  
Nov-10-21 07:00AM  
Nov-01-21 01:54PM  
Oct-22-21 04:30PM  
Oct-15-21 08:43AM  
Oct-07-21 02:02PM  
Oct-06-21 10:20PM  
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-variant inhibitor for activating and resistance mutations of the KIT kinase or a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors (GIST), a type of cancer characterized by oncogenic activation of KIT. The company also develops fourth-generation EGFR inhibitor that is active against C797S, an EGFR mutation that causes resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GORDON CARL LDirectorJan 21Buy9.97111,8961,115,60316,542,652Jan 21 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 21Buy9.97111,8961,115,60316,542,652Jan 21 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 20Buy9.9535,000348,25016,430,756Jan 21 07:18 PM
GORDON CARL LDirectorJan 20Buy9.9535,000348,25016,430,756Jan 21 07:22 PM
GORDON CARL LDirectorJan 19Buy9.9711,521114,86416,395,756Jan 21 07:22 PM
ORBIMED ADVISORS LLCDirectorJan 19Buy9.9711,521114,86416,395,756Jan 21 07:18 PM
GORDON CARL LDirectorJan 13Buy9.4317,320163,32816,384,235Jan 13 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 13Buy9.4317,320163,32816,384,235Jan 13 07:18 PM
ORBIMED ADVISORS LLCDirectorJan 12Buy10.0618,897190,10416,366,915Jan 13 07:18 PM
GORDON CARL LDirectorJan 12Buy10.0618,897190,10416,366,915Jan 13 07:27 PM
GORDON CARL LDirectorJan 11Buy10.518,50089,31916,348,018Jan 13 07:27 PM
ORBIMED ADVISORS LLCDirectorJan 11Buy10.518,50089,31916,348,018Jan 13 07:18 PM
CLACKSON TIMOTHY PPresident and CEODec 21Buy9.762,60025,381348,530Dec 22 06:26 PM
Dahms Bradford D.Chief Financial OfficerDec 21Buy10.151,97020,0001,970Dec 22 06:21 PM